Stock · LLY · Healthcare
United States · Large Cap · listed since 1978 · Revenue 12 mo. $79.7B
Price as of 11/06/2026
Summary
58.5 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €8.1B (2025), it supports €89.5B. The remaining €997.9B of the market value assume it grows more than 30% a year for 10 years and not at all afterwards.
Required FCF growth per year
over 30%
no growth afterwards
Price to operating cash flow 43.1×, within its usual range.
Middle half of 20 quarters: 38.8× to 80.7×, median 53.0×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
AI summary of the 2025 annual report
A language model selected and condensed statements from the report. Each statement carries a verbatim quote. The selection is not complete and shows the state of the report. It gives no rating and does not feed into the score.
Form 10-K, fiscal year ended 12/31/2025, filed 02/12/2026. Open the report at the SEC
The company discovers, develops, manufactures and markets products in one business segment.
We discover, develop, manufacture, and market products in a single business segmentIn certain jurisdictions, LillyDirect, a direct-to-patient digital health care platform, delivers select Lilly medicines that third-party pharmacies dispense to patients.
In certain jurisdictions, we utilize LillyDirect, our direct-to-patient digital health care platform, to provide delivery of select Lilly medicines dispensed by third-party pharmacies to patients.Anti-obesity medicines make up a significant portion of the company's revenues.
Our anti-obesity medicines comprise a significant portion of our revenuesThe company's products are sold in approximately 90 countries.
Our products are sold in approximately 90 countries.Account managers serve wholesalers, pharmacy benefit managers, insurers, employers, hospitals and certain retail pharmacies.
Our account managers service wholesalers, pharmacy benefit managers, insurers, plan sponsors, employers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies.Patients who pay themselves buy through LillyDirect, and these sales made up a growing part of the business in 2025.
In addition, patient self-pay sales through LillyDirect represented a growing portion of our business in 2025The company's products compete worldwide with many other pharmaceutical products in highly competitive markets.
Our products compete globally with many other pharmaceutical products in highly competitive markets.Important factors in competition include effectiveness, safety, availability, ease of use, patient preference, price, and payer coverage and reimbursement rates.
Important competitive factors include effectiveness, safety, availability, ease of use, patient preference, and overall experience; formulary placement, price, payer coverage and reimbursement rates, and demonstrated cost-effectivenessGeneric medicines and biosimilars can pose major competitive challenges to the company's business.
Generic pharmaceuticals and biosimilars can pose major competitive challenges to our business.Trulicity will lose significant patent and remaining data protection in the next few years.
For example, Trulicity will lose significant patent and remaining data protections in the next few years.Mounjaro and Zepbound accounted for 56 percent of the company's total revenues in 2025.
In particular, Mounjaro and Zepbound accounted for 56 percent of our total revenues in 2025In August 2023, HHS selected Jardiance for government-set prices in Medicare, effective from 2026, at a significant discount.
In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices in Medicare (effective beginning in 2026) at a significant discountChanges to the 340B program or the Medicaid programs could have a material adverse impact on the business.
Changes to the 340B program or the Medicaid programs could have a material adverse impact on our business.The company continues to see counterfeit, misbranded, adulterated and mass-compounded incretin drugs sold in the U.S. and other markets.
We continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins in the U.S. and other markets.Since the last quarter
Q1 → Q2 2026
2 more unchanged: Gross margin, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 77.78% | 11.52% | Rank 98 |
| Return on capital (Greenblatt) | 65.88% | 32.55% | Rank 80 |
| EBIT margin | 45.56% | 18.31% | Rank 96 |
| FCF margin | 13.77% | 14.12% | Rank 47 |
| Gross margin | 83.04% | 60.99% | Rank 90 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 44.70% | 8.04% | Rank 94 |
| Earnings growth, 3 years per year | 51.79% | 5.44% | Rank 92 |
| Earnings growth, 5 years per year | 28.84% | 7.00% | Rank 92 |
| Sustainable growth (ROE × retained earnings) | 12.03% | 3.66% | Rank 94 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 1.70% | 2.90% | Rank 21 |
| FCF yield | 0.74% | 3.63% | Rank 11 |
| EV/saleslower is better | 19.13 | 4.03 | Rank 5 |
| EV/EBITlower is better | 41.99 | 21.73 | Rank 13 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 34.83% | 8.66% | Rank 80 |
| Share price, 6 months | 43.24% | 24.27% | Rank 81 |
| Share price, 3 months | 19.32% | 15.42% | Rank 64 |
| Distance from 52-week high | −4.51% | −7.35% | Rank 62 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 15.48% | 0.30% | Rank 5 |
| Change in share countlower is better | −0.67% | 0.00% | Rank 62 |
| Dividend streak in years | 53 | 10 | Rank 99 |
| Price reaction to results, market-adjusted | 6.68% | 0.05% | Rank 91 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 23.59% | 48.40% | Rank 13 |
| Net debt/EBITDAlower is better | 1.11 | 1.11 | Rank 50 |
| Debt to equitylower is better | 1.60 | 0.48 | Rank 12 |
| Volatility, 1 yearlower is better | 35.47% | 31.42% | Rank 37 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 21.2 | 18.2% | 3.8 | 1.10B | 5.7 |
| 2017 | 20.0 | 21.3% | 3.5 | 1.05B | 7.1 |
| 2018 | 21.5 | 28.0% | 2.5 | 1.03B | 3.0 |
| 2019 | 22.3 | 26.9% | 3.5 | 958M | 13.5 |
| 2020 | 24.5 | 29.4% | 4.5 | 957M | 12.9 |
| 2021 | 28.3 | 28.0% | 5.4 | 954M | 13.1 |
| 2022 | 28.5 | 30.3% | 4.6 | 950M | 14.2 |
| 2023 | 34.1 | 31.6% | −3.2 | 903M | 22.4 |
| 2024 | 45.0 | 37.8% | 3.8 | 904M | 30.4 |
| 2025 | 65.2 | 45.6% | 9.0 | 898M | 35.3 |
5 of 7 StockScorer Score rules met · How the score is built
Eli Lilly and Company mainly meets criteria in the Growth category. Result from 18 strategies checked.
Eli Lilly and Company is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
5 of 7 rules met
7 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Eli Lilly and Company.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 58.9 | 30.0 |
| P/B ratio | 45.8 | 4.8 |
| Return on equity (ROE) | 77.8% | 11.5% |
| Equity ratio | 23.6% | 48.4% |
| Debt-to-equity (D/E) | 1.60 | 0.48 |
| Dividend yield | 0.5% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| LLY | Eli Lilly and Companythis page | |
| JNJ | Johnson & Johnson | High6.4 |
| ABBV | AbbVie Inc | Medium5.5 |
| MRK | Merck & Company Inc | Medium5.5 |
| ROP.SW | Roche Holding AG | locked |
| NOVN.SW | Novartis AG | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.